Jae-Wan Jung

Dr. Jae-Wan Jung

John Innes Centre

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
HPHadrien Peyret
Hadrien Peyret
JSJohn F. C. Steele
John F. C. Steele
JJJae-Wan Jung
Jae-Wan Jung
ETEva Thuenemann
Eva Thuenemann
YMYulia Meshcheriakova
Yulia Meshcheriakova
GLGeorge Lomonossoff
George Lomonossoff
The past 30 years have seen the growth of plant molecular farming as an approach to the production of recombinant proteins for pharmaceutical and biotechnological uses. Much of this effort has focused on producing vaccine candidates against viral diseases, including those caused by enveloped viruses. These represent a particular challenge given the difficulties associated with expressing and purifying membrane-bound proteins and achieving correct assembly. Despite this, there have been notable successes both from a biochemical and a clinical perspective, with a number of clinical trials showing great promise. This review will explore the history and current status of plant-produced vaccine candidates against enveloped viruses to date, with a particular focus on virus-like particles (VLPs), which mimic authentic virus structures but do not contain infectious genetic material.

11 August 2022 in Molecules
Verified
Journal Article
Open access
PDF file
JBJuliette Balieu
Juliette Balieu
JJJae-Wan Jung
Jae-Wan Jung
PCPhilippe Chan
Philippe Chan
GLGeorge Lomonossoff
George Lomonossoff
PLPatrice Lerouge
Patrice Lerouge
MBMuriel Bardor
Muriel Bardor
The emergence of the SARS-CoV-2 coronavirus pandemic in China in late 2019 led to the fast development of efficient therapeutics. Of the major structural proteins encoded by the SARS-CoV-2 genome, the SPIKE (S) protein has attracted considerable research interest because of the central role it plays in virus entry into host cells. Therefore, to date, most immunization strategies aim at inducing neutralizing antibodies against the surface viral S protein. The SARS-CoV-2 S protein is heavily glycosylated with 22 predicted N-glycosylation consensus sites as well as numerous mucin-type O-glycosylation sites. As a consequence, O- and N-glycosylations of this viral protein have received particular attention. Glycans N-linked to the S protein are mainly exposed at the surface and form a shield-masking specific epitope to escape the virus antigenic recognition. In this work, the N-glycosylation status of the S protein within virus-like particles (VLPs) produced in Nicotiana benthamiana (N. benthamiana) was investigated using a glycoproteomic approach. We show that 20 among the 22 predicted N-glycosylation sites are dominated by complex plant N-glycans and one carries oligomannoses. This suggests that the SARS-CoV-2 S protein produced in N. benthamiana adopts an overall 3D structure similar to that of recombinant homologues produced in mammalian cells.